Abstract Background/Objective Before approval of andexanet alfa, off‐label treatment with 4‐
factor prothrombin complex concentrate (4F‐PCC) was often utilized for the management of …

Andexanet-alpha is a specific reversal agent for direct factor Xa inhibitors (dFXaI). We aimed
to project utilization rates and cost of andexanet for reversal of dFXaI-related major …

OBJECTIVES: To combine evidence on andexanet alfa and prothrombin complex
concentrates for factor Xa inhibitor-associated bleeding to guide clinicians on reversal …

Aim: We describe the real-world utilization and outcomes associated with managing oral
factor Xa inhibitor (FXai)-related major bleeds. Materials & methods: Electronic records from …

Objective Direct factor Xa inhibitors rivaroxaban and apixaban are efficacious alternatives to
warfarin and confer a lower risk of spontaneous intracranial hemorrhage (ICH); however …

Background and Purpose—In the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial,
80 μg/kg of recombinant activated factor VII (rFVIIa) significantly reduced intracerebral …

Objective To investigate parameters associated with hematoma enlargement in non–vitamin
K antagonist oral anticoagulant (NOAC)‐related intracerebral hemorrhage (ICH). Methods …

Oral factor Xa (fXa) inhibitor-related bleeding is a concerning drug safety problem. There is
considerable controversy surrounding available reversal strategies. The recently approved …

Abstract Background and Purpose Ultra-early hemostatic therapy may improve outcome
after intracerebral hemorrhage (ICH) by preventing rebleeding and hematoma expansion …

The aim of the present European Stroke Organisation guideline document is to provide
clinically useful evidence-based recommendation on reversal of anticoagulant activity VKA …